The 18-month study is expected to cost approximately $6 million and will be jointly funded by TGen and Kronos, a subsidiary of Kronos Optimal Health. Both are located in
In the study, researchers will examine some 570,000 SNPs from deceased individuals who were confirmed to have Alzheimer's disease at autopsy, and another 1,000 dead who were confirmed to be free of the disease at autopsy. DNA samples will be obtained from brain banks in the
Kronos will have an exclusive worldwide license to all intellectual property that results from the research, and will look to develop a diagnostic for genetic predisposition.